Semaglutide and empagliflozin can be prescribed together, and trials have studied the pair in type 2 diabetes. They work by different routes, so a provider may combine them. Whether that fits you is a medical call, made through TelosRX after review.
Two of the most talked-about metabolic drugs of the decade come from different families. Semaglutide is a GLP-1 receptor agonist. Empagliflozin is an SGLT2 inhibitor. People search "semaglutide and empagliflozin" because they're on one and wonder about the other.
This explainer covers what each drug does, why they get paired, what the research found, and what to ask before stacking them. Everything here is general information. Any change to your medications is subject to medical approval by a licensed provider.
What Is Semaglutide?
Semaglutide copies GLP-1, a gut hormone released after you eat. It slows stomach emptying, boosts insulin when blood sugar rises, and quiets appetite signals in the brain. That last effect is why it shows up in weight-management care.
Commercial semaglutide is sold as Ozempic (type 2 diabetes), Wegovy (chronic weight management) and Rybelsus (oral, type 2 diabetes). Each brand is FDA-approved for the indications on its label. Compounded semaglutide is a different thing: it is not FDA-approved. If you want the basics first, read our guide on how semaglutide works.
What Is Empagliflozin?
Empagliflozin is sold as Jardiance. It belongs to the SGLT2 inhibitor class, short for sodium-glucose cotransporter 2 blockers. In plain English, it makes your kidneys pass extra glucose into urine.
That glucose loss lowers blood sugar without pushing the pancreas harder. It also carries a modest calorie loss and a mild diuretic effect. Empagliflozin is FDA-approved for glycemic control in type 2 diabetes. Its label also covers lowering cardiovascular death risk in some adults, plus heart failure and chronic kidney disease indications.
Semaglutide and Empagliflozin: How the Mechanisms Differ
The pair gets attention because the two drugs don't overlap much. One acts on the gut-brain-pancreas axis. The other acts on the kidney. Here's the quick version.
| Feature | Semaglutide | Empagliflozin |
|---|---|---|
| Drug class | GLP-1 receptor agonist | SGLT2 inhibitor |
| Main site of action | Gut, pancreas, brain | Kidney |
| How it lowers glucose | Glucose-dependent insulin release, less glucagon | Sends excess glucose out in urine |
| Appetite effect | Strong appetite reduction | Minimal |
| Form | Weekly injection or daily tablet | Daily tablet |
| Common side effects | Nausea, constipation, reflux | Genital yeast infections, more urination |
| Key brand names | Ozempic, Wegovy, Rybelsus | Jardiance |
Because the pathways differ, the effects can add up rather than cancel out. That's the theory. The trials below show how it has played out so far.
Can You Take Semaglutide and Empagliflozin Together?
Yes, the combination is used in practice and has been studied. Diabetes guidelines allow a GLP-1 drug and an SGLT2 inhibitor in the same plan when a clinician sees a reason. There is no known direct drug-drug interaction between the two.
That doesn't make the combo right for everyone. Two drugs mean two sets of side effects. Both can reduce fluid intake or increase fluid loss, so dehydration is a real concern. A provider will check kidney function, other medications and your goals first.
If weight management is your main goal, a GLP-1 pathway on its own is often the starting point. You can see what a provider-reviewed plan looks like on our semaglutide page. Eligibility is subject to medical approval by a licensed provider.
What the Research Shows on the Combination
Combination data is newer than single-drug data. Most of it comes from people with type 2 diabetes. Here are the main findings so far.
SUSTAIN 9: Semaglutide Added to an SGLT2 Inhibitor
SUSTAIN 9 enrolled 302 adults with type 2 diabetes already taking an SGLT2 inhibitor. Adding weekly semaglutide for 30 weeks lowered HbA1c and body weight more than placebo. Gastrointestinal side effects were the most common complaint, per the published trial in The Lancet Diabetes & Endocrinology.
The Aarhus 32-Week Trial: Separate vs Combined
A Danish trial split 120 adults with type 2 diabetes into four groups: placebo, semaglutide, empagliflozin, or both. The combination lowered 24-hour systolic blood pressure by about 10 mmHg. That beat either drug alone, according to the 2024 report in Diabetes, Obesity and Metabolism.
Time in healthy glucose range rose from 72% to 91% on the combination, without more lows. Arterial stiffness did not change in any group. A companion paper found neither drug improved kidney oxygenation as hoped.
Studies Still Running
Trials are now testing the pair in fatty liver disease and type 1 diabetes. One is listed on ClinicalTrials.gov (NCT06894784). Results are pending, so read early claims about these uses with caution.
Side Effects to Know About
Each drug brings its own profile. Together, a few risks deserve extra attention.
- Dehydration: GLP-1 drugs can cut thirst and food intake. SGLT2 inhibitors increase urination. Low fluid intake on both can strain the kidneys.
- Stomach upset: Nausea, constipation and reflux come mainly from semaglutide, especially during dose increases.
- Genital and urinary infections: Extra glucose in urine raises yeast infection risk on empagliflozin.
- Ketoacidosis: SGLT2 inhibitors carry a rare risk of diabetic ketoacidosis, sometimes with near-normal glucose. Very low carb intake or illness can raise it.
- Low blood sugar: Neither drug causes many lows alone. The risk rises if insulin or a sulfonylurea is also in the mix.
Seek care right away for severe belly pain, vomiting you can't keep fluids through, or unusual fatigue and fast breathing.
Who Might a Provider Consider for Both?
Providers usually think about this pairing for adults with type 2 diabetes who need more glucose control. Heart or kidney risk can tip the decision, since both classes have outcome data there. People without diabetes rarely need an SGLT2 inhibitor for weight alone.
If you're comparing GLP-1 options first, our breakdown of tirzepatide vs semaglutide is a good next read. You can also review semaglutide benefits in more depth.
How TelosRX Handles Combination Questions
TelosRX is an online-first, asynchronous telehealth service. You complete a health intake on your own time. A licensed provider reviews it, including every medication you list.
If you already take empagliflozin, say so in your intake. The provider weighs it before any GLP-1 decision. Approval is subject to medical approval by a licensed provider and is never guaranteed. Compounded GLP-1 medications are not FDA-approved.
Frequently Asked Questions
Is it safe to take semaglutide and empagliflozin together?
Trials like SUSTAIN 9 found the combination was generally tolerated in adults with type 2 diabetes. Stomach side effects were most common. Safety depends on your kidney function, hydration, other medications and health history. That's why the decision belongs to a licensed provider who can review your full picture and order labs when needed.
What's the difference between semaglutide and empagliflozin?
Semaglutide is a GLP-1 receptor agonist that slows digestion, supports insulin release and reduces appetite. Empagliflozin is an SGLT2 inhibitor that makes the kidneys pass extra glucose into urine. Semaglutide is usually a weekly injection. Empagliflozin is a daily tablet. They act on different organs, which is why they are sometimes combined.
Does empagliflozin help with weight loss like semaglutide?
Empagliflozin causes some calorie loss through urine, so modest weight change is common. Its effect on appetite is minimal, though. Semaglutide works mainly by reducing hunger and slowing digestion, so its weight effect is typically larger. Empagliflozin is not FDA-approved for weight management. Wegovy, a semaglutide brand, carries a chronic weight management indication.
Can you drink alcohol on semaglutide and empagliflozin?
Alcohol adds dehydration risk, and both drugs already affect fluid balance. Heavy drinking also raises ketoacidosis risk on SGLT2 inhibitors. Small amounts may be acceptable for some people, but this varies. Ask your provider before drinking, and never drink on an empty stomach while on either medication. Hydrate well if you do.
What side effects should I watch for on both drugs?
Watch for nausea, constipation, frequent urination, thirst, dizziness and genital itching. Get urgent care for severe abdominal pain, persistent vomiting, rapid breathing, confusion or extreme fatigue, since these can signal dehydration or ketoacidosis. Report any new symptom to your provider. Dose changes or pauses should only happen with their guidance.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.